Average Insider

Where insiders trade, we follow

$INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Healthcare
Sector
Biotechnology
Industry
Jennifer S. Buell
CEO
23
Employees
$9.38
Current Price
$58.21M
Market Cap
52W Low$8.48
Current$9.3810.7% above low, 89.3% below high
52W High$16.93

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells11$73,265.286,938
3 monthsBuys00--All Sells
Sells11$73,265.286,938
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Oct 12, 2026
Buell Jennifer
Director
Sale6,938$10.56$73,265.28View Details
8 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 13, 2026
EPS
Estimated-$0.50
ActualN/A
Revenue
Estimated$875.00K
ActualN/A
Nov 12, 2026
EPS
Estimated-$0.50
ActualN/A
Revenue
Estimated$875.00K
ActualN/A
Nov 11, 2026
EPS
Estimated-$0.66
Actual-$0.50
Beat
Revenue
Estimated$75.00K
Actual$200.00K
Beat
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1